Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Assets: 2022-2025

Historic Other Non-Current Assets for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $721,000.

  • Stoke Therapeutics' Other Non-Current Assets rose 45.95% to $721,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $721,000, marking a year-over-year increase of 45.95%. This contributed to the annual value of $721,000 for FY2024, which is 26.71% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Other Non-Current Assets stood at $721,000, which was down 0.00% from $721,000 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Other Non-Current Assets ranged from a high of $721,000 in Q4 2024 and a low of $494,000 during Q2 2024.
  • In the last 3 years, Stoke Therapeutics' Other Non-Current Assets had a median value of $569,000 in 2024 and averaged $610,636.
  • Per our database at Business Quant, Stoke Therapeutics' Other Non-Current Assets declined by 13.18% in 2024 and then surged by 45.95% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Other Non-Current Assets (Quarterly) stood at $569,000 in 2022, then remained steady at $569,000 in 2023, then rose by 26.71% to $721,000 in 2024, then surged by 45.95% to $721,000 in 2025.
  • Its last three reported values are $721,000 in Q3 2025, $721,000 for Q2 2025, and $721,000 during Q1 2025.